FinLantern, in collaboration with Westmount Capital, would like to invite you to a first Lugano presentation by Maricann Group, a publicly traded Canadian Medical Cannabis company (MARI on CSE; 75M on Frankfurt; MRRCF on OTCMKTS), which was founded in 2013 in Langton, Ontario.
Maricann is a federally licensed (Ottawa, Canada and Dresden, Saxony, Germany) cannabis producer serving thousands of patients. Company is currently expanding its cultivation, extraction analytics, and production facilities to prepare for growth into the adult-use, liberalized cannabis market in Canada, and internationally, notably in Germany and in Switzerland, ultimately into mature and developing cannabis markets worldwide.
Maricann GmbH of Munich, Germany is a 95%-owned subsidiary of Maricann Netherlands BV, a 100% wholly-owned subsidiary of Maricann Group Inc.
On May 10th, 2018 Company has announced the acquisition of Haxxon AG, in Switzerland, which forms a critical element of Maricann’s European expansion. Maricann is now positioned to enter the Swiss market through Haxxon’s production of feminized high CBD cannabis plants. Haxxon operates a 6,000 sq.m. indoor facility in Regensdorf, an industrial suburb of Zurich, about 10 minutes from Kloten Airport.
Maricann has 133,389,652 shares issued and outstanding and at $1.79 closing price May 22nd, MARI has a Market Cap of $239 million.
For further information, please go to www.maricann.com
For a Stock Quote:
Company will be presented by Benjamin Ward, CEO.
Since October 2016 with Maricann Group as CEO & Director.
Ben leads all facets of the company’s operations, including its strategic direction and execution, finance and industry relations. He brings extensive domestic and global experience in business development, infrastructure development and capital markets to his leadership of Maricann.
Ben holds a BA (Honors) and an MBA from Bradford University School of Management (England), the latter with a dual concentration in Operations and Finance.
Check out Ben Ward’s profile on Linked-In: